Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Prostate Cancer
Comparing the Impact of ADT Agents on Cardiovascular Events and Death in Men with Prostate Cancer
By
Rosemary Frei, MSc
Personalized Medicine
,
Prostate Cancer
July 2013, Vol 4, No 6
Niagara Falls, Ontario—Among men with prostate cancer and preexisting cardiovascular (CV) disease, the risk of CV events or CV-related death is cut in half when they receive androgen-deprivation therapy (ADT) with degarelix (Firmagon) instead of the luetinizing hormone–releasing hormone (LHRH) agonists goserelin (Zoladex) or leuprolide (Lupron), according to results of a new analysis presented at the 2013 Canadian Urological Association annual meeting.
Read Article
Two Genetic Tests Can Prevent Overtreatment of Early Prostate Cancer
By
Phoebe Starr
Personalized Medicine
,
Prostate Cancer
July 2013, Vol 4, No 6
The management of patients with prostate cancer will be advanced by 2 new genetic tests—Oncotype DX prostate cancer test and Prolaris.
Read Article
Strongly Suppressing Testosterone during Androgen-Deprivation Therapy Prolongs Survival
Personalized Medicine
,
Prostate Cancer
,
Solid Tumors
June 2013, Vol 4, No 5
A secondary analysis of a large study on intermittent versus continuous androgen-deprivation therapy (ADT) has confirmed the importance of aiming for very low testosterone levels in men after they are diagnosed with prostate cancer, according to new data presented at the 2013 Canadian Urological Association annual meeting.
Read Article
New Guideline Emphasizes Sequenced Therapy for Castration-Resistant Prostate Cancer
Personalized Medicine
,
Prostate Cancer
,
Solid Tumors
June 2013, Vol 4, No 5
Evidence-based drug sequencing should form the basis of treatment for castration-resistant prostate cancer (CRPC), according to a new guideline from the American Urological Association (AUA) released at the 2013 AUA annual meeting.
Read Article
Budget Impact Model: Epigenetic Assay Can Help Avoid Unnecessary Repeated Prostate Biopsies, Reduce Spending
Prostate Cancer
,
Solid Tumors
May 2013, Vol 4, No 4
This is an abbreviated version of the original article that was recently published in American Health & Drug Benefits. 2013;6(1):15-24.
Read Article
AUA Revises Its Guidelines for Prostate Cancer PSA Screening
By
Charles Bankhead
Prostate Cancer
,
Solid Tumors
May 2013, Vol 4, No 4
Prostate cancer screening with prostate-specific antigen (PSA) tests should focus on men aged 55 to 69 years, the group that is the most likely to benefit from screening, according to a new clinical guideline issued by the American Urological Association (AUA) at its 2013 annual meeting.
Read Article
Preventive Therapy Preserves Sexual Function after Radiotherapy for Patients with Prostate Cancer
By
Charles Bankhead
Prostate Cancer
February 2013, Vol 4, No 2
Boston, MA—Patients with prostate cancer reported significantly better sexual function for up to 2 years after radiation therapy when they took sildenafil (Viagra) on a daily basis during and after treatment, according to results of a placebo-controlled clinical trial.
Read Article
Exploring Men’s Willingness to Pay for Prostate Cancer Screening to Avoid Unnecessary Biopsy and Treatment
By
Rosemary Frei, MSc
Prostate Cancer
February 2013, Vol 4, No 2
>Dutch researchers have peered into the minds and wallets of a group of men aged 55 to 75 years to determine what they are willing to trade for a reduced risk of prostate cancer–related death or to avoid unnecessary procedures and treatment.
Read Article
Which Patients with Prostate Cancer Should Receive Hormone Therapy in Addition to Radiation?
By
Phoebe Starr
Personalized Medicine
,
Prostate Cancer
,
Solid Tumors
February 2012, Vol 3, No 1
Read Article
Physician-Led Approach Can Cut Unnecessary Testing in Prostate Cancer
By
Caroline Helwick
Personalized Medicine
,
Prostate Cancer
,
Solid Tumors
February 2012, Vol 3, No 1
Feedback from their peers helped physicians refrain from ordering unnecessary tests for patients with newly diagnosed cancer, according to a recent study (Miller DC, et al. J Urol. 2011;186:844-849. Epub 2011 Jul 23).
Read Article
Page 7 of 8
1
2
3
4
5
6
7
8
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
Wayne Kuznar
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma